Development and characterization of a novel lipohydrogel nanocarrier: Repaglinide as a lipophilic model drug

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 4, 2016, Pages 450-458

  Ebrahimi, Hossein Ali ^a,b,c   Javadzadeh, Yousef ^a,b   Hamidi, Mehrdad ^c,d   Barzegar Jalali, Mohammad ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

chitosan; lipohydrogel; nanocarrier; repaglinide; solid lipid nanoparticles

Indexed keywords

GLUCOSE; LIPOHYDROGEL NANOCARRIER; NANOCARRIER; REPAGLINIDE; SOLID LIPID NANOPARTICLE; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; CHITOSAN; DELAYED RELEASE FORMULATION; DRUG CARRIER; GLUCOSE BLOOD LEVEL; HYDROGEL; LIPID; PIPERIDINE DERIVATIVE; POLYPHOSPHATE; TRIPHOSPHORIC ACID;

ARTICLE; CELL CULTURE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CYTOTOXICITY TEST; DRUG DELIVERY SYSTEM; DRUG RELEASE; GLUCOSE BLOOD LEVEL; INFRARED SPECTROSCOPY; LIPOPHILICITY; MATERIAL COATING; MICROSCOPY; MTT ASSAY; PARTICLE SIZE; PRODUCT DEVELOPMENT; STATIC ELECTRICITY; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG FORMULATION; FIBROBLAST; HYDROGEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MOUSE; NANOTECHNOLOGY; PATHOLOGY; PHARMACEUTICS; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; SURFACE PROPERTY;

ADMINISTRATION, INTRAVENOUS; ANIMALS; BLOOD GLUCOSE; CARBAMATES; CELL LINE; CELL SURVIVAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; FIBROBLASTS; HYDROGELS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MICE; NANOTECHNOLOGY; PARTICLE SIZE; PIPERIDINES; POLYPHOSPHATES; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 84965165021     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12537     Document Type: Article

References (49)

1. Mehnert W, Mäder K,. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165-196.
2. MuÈller RH, et al,. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
3. zur Mühlen A, et al,. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149-155.
4. Müller RH, et al,. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54 (Suppl. 1): S131-S155.
5. Wong HL, et al,. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491-504.
6. Moghimi SM, Szebeni J,. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42: 463-478.
7. Müller RH, et al,. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002; 242: 121-128.
8. Jores K, et al,. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Controlled Release 2004; 95: 217-227.
9. Souto EB, et al,. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278: 71-77.
10. Fundarò A, et al,. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol Res 2000; 42: 337-343.
11. Lainé A-L, et al,. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring. J Controlled Release 2014; 188: 1-8.
12. Rosario Pignatello AL, et al,. Evaluation of new amphiphilic PEG derivatives for preparing stealth lipid nanoparticles. Colloids Surf A Physicochem Eng Aspects 2013; 434: 136-144.
13. Schubert MA, Müller-Goymann CC,. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005; 61: 77-86.
14. Bocca C, et al,. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 1998; 175: 185-193.
15. Sarmento B, et al,. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polym 2011; 84: 919-925.
16. Ying XY, et al,. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym 2011; 84: 1357-1364.
17. Soo PL, et al,. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur J Pharm Biopharm 2008; 69: 149-157.
18. Muzzarelli RA, et al,. Chitosan taurocholate capacity to bind lipids and to undergo enzymatic hydrolysis: an in vitro model. Carbohydr Polym 2006; 66: 363-371.
19. Hwang HY, et al,. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Controlled Release 2008; 128: 23-31.
20. Zhang J, et al,. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomed Nanotechnol Biol Med 2007; 3: 258-265.
21. Garcia-Fuentes M, et al,. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur J Pharm Sci 2005; 25: 133-143.
22. Souto EB, et al,. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm 2004; 58: 83-90.
23. Pandit AA, Dash AK,. Surface-modifed solid lipid nanoparticulate formulation for ifosfamide: development and characterization. Nanomedicine 2011; 6: 1397-1412.
24. Casadei MA, et al,. Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations. Int J Pharm 2006; 325: 140-146.
25. Grenha A, et al,. Microspheres containing lipid/chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur J Pharm Biopharm 2008; 69: 83-93.
26. Dharmala K, et al,. Development of chitosan-SLN microparticles for chemotherapy: in vitro approach through efflux-transporter modulation. J Controlled Release 2008; 131: 190-197.
27. Dufort S, et al,. Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev 2012; 64: 179-189.
28. Wissing SA, et al,. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257-1272.
29. Almeida AJ, Souto E,. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 2007; 59: 478-490.
30. Blasi P, et al,. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59: 454-477.
31. Ruzilawati AB, et al,. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal 2007; 43: 1831-1835.
32. Wyman JF, et al,. Simple procedure for jugular vein cannulation of rats. Toxicol Methods 1994; 4: 12-18.
33. Thrivikraman KV, et al,. Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res Protoc 2002; 10: 84-94.
34. Hamidi M, et al,. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008; 60: 1638-1649.
35. Silva AC, et al,. Solid lipid nanoparticles (SLN)-based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: preparation and characterization studies. Colloids Surf B 2012; 93: 241-248.
36. Verma VK, Alpana R,. Development of piroxicam loaded SLN-base hydrogel for transdermal delivery. Int J Pharm Sci Nanotechnol 2014; 7: 2338-2345.
37. Paolicellia P, et al,. The system SLN-dextran hydrogel: an application for the topical delivery of ketoconazole. J Chem Pharm Res 2011; 3: 410-421.
38. Trotta M, et al,. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003; 257: 153-160.
39. Rawat MK, et al,. Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. Curr Drug Deliv 2010; 7: 44-50.
40. Han F, et al,. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf A 2008; 315: 210-216.
41. Honary S, Zahir F,. Effect of zeta potential on the properties of nano-drug delivery systems-a review (part 2). Trop J Pharm Res 2012; 12: 265-273.
42. Rodino S, et al,. Spectrophotometric method for quantitative determination of nystatin antifungal agent in pharmaceutical formulations. Dig J Nanomater Biostruct 2014; 9: 1215-1222.
43. Butu A, et al,. Liposomal nanodelivery system for proteasome inhibitor anticancer drug bortezomib. Farmacia 2015; 63: 224-229.
44. Barbat C, et al,. Microencapsulation of the allelochemical compounds and study of their release from different products. Dig J Nanomater Biostruct 2013; 8: 945-953.
45. Kafshgari MH, et al,. Reinforcement of chitosan nanoparticles obtained by an ionic cross-linking process. Iran Polym J 2010; 20: 445-456.
46. Xu Y, Du Y,. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003; 250: 215-226.
47. Gierszewska-Druzyńska M, Ostrowska-Czubenko J,. The effect of ionic crosslinking on thermal properties of hydrogel chitosan membranes. Prog Chem Appl 2010; 15: 25-32.
48. Pelczarska A, et al,. New high throughput screening method for drug release measurements. Eur J Pharm Biopharm 2013; 85: 151-157.
49. Schipper NGM, et al,. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 1996; 13: 1686-1692.